Altre lingue Iconovo AB

Azioni

ICO

SE0010868943

Tempo differito Nasdaq Stockholm Altri mercati azionari 12:54:44 30/04/2024			Variaz. 5gg	Var. 1 gen.
8,1 ^SEK	+1,50%		+1,25%	-29,87%

25/04	Iconovo AB (publ) riporta i risultati degli utili per il primo trimestre terminato il 31 marzo 2024	CI
11/03	Iconovo AB (publ) e Affilogic presenteranno i dati positivi di uno studio di fattibilità sulle nanofitine in ICOone	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Iconovo Q1 - Solid quarter with a near-term catalyst on the horizon	26/04
Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Iconovo to present positive data from a feasibility study on Nanofitins® in ICOone®	11/03
Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone	11/03
Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea	05/03
Iconovo Q4 - Aligned with our expectations and a directed issue announcement	19/02
Iconovo AB Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Iconovo AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02
Iconovo carries out a directed share issue of SEK 33.3 million, partly subject to subsequent approval by the Extraordinary General Meeting, and brings forward the publication of the year-end report	15/02
Iconovo signs additional contract with Kiox Pharma for the development of a new inhalable treatment for interstitial lung disease	07/02
Iconovo AB Signs Additional Contract with Kiox Pharma for the Development of A New Inhalable Treatment for Interstitial Lung Disease	07/02
Iconovo launches improved versions of nasal ICOone® inhalers	06/02
Iconovo AB Launches Improved Versions of Nasal ICOone Inhalers	06/02
Iconovo receives order from Top-10 Pharma company for evaluation of multi-dose inhaler	01/02
Iconovo Receives Order from Top-10 Pharma Company for Evaluation of Multi-Dose Inhaler	01/02
Iconovo recruits Gary Pitcairn (PhD) as Senior Scientific Advisor	08/01
Redeye Initiates Coverage of Iconovo	06/12
Iconovo AB changes liquidity provider and Certified Adviser to Carnegie Investment Bank AB (publ)	30/11
Nomination Committee appointed at Iconovo AB	29/11
BioStock: Busy days for Iconovo at BIO-Europe	20/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Iconovo AB

Azioni

ICO

SE0010868943

Altre lingue

Filtri